The results of this study found that the levels of CYFRA21-1, CA125, and VGEF in the treatment group after treatment were significantly lower than those before treatment in the control group, indicating that PD-1/PD-L1 inhibitor chemotherapy combined with Lung Cancer Fang No. 1 therapy can effectively inhibit tumor cell proliferation and control of the condition of SCLC patients. This evidence concerns the gene RPL17 and small cell lung carcinoma.